Perigon Wealth Management, LLC Nektar Therapeutics Transaction History

Perigon Wealth Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$16.56 - $25.46 $74,867 - $115,104	-4,521 Closed	0 $0
Q4 2020 Jan 28, 2021	BUY	$15.77 - $19.03 $71,296 - $86,034	4,521 New	4,521 $77,000
Q3 2020 Nov 03, 2020	SELL	$16.59 - $24.79 $143,437 - $214,334	-8,646 Closed	0 $0
Q2 2020 Jul 29, 2020	BUY	$16.86 - $23.44 $145,771 - $202,662	8,646 New	8,646 $200,000
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $160,173 - $235,087	-5,072 Closed	0 $0
Q4 2018 Feb 11, 2019	BUY	$30.43 - $56.65 $2,130 - $3,965	70 Added 1.4%	5,072 $223,000
Q3 2018 Nov 13, 2018	SELL	$46.46 - $68.49 $52,546 - $77,462	-1,131 Reduced 18.44%	5,002 $305,000
Q2 2018 Aug 09, 2018	BUY	$46.25 - $104.45 $283,651 - $640,591	6,133 New	6,133 $299,000
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $116,458 - $306,069	-5,059 Closed	0 $0
Q3 2017 Dec 05, 2017	BUY	$17.79 - $24.0 $89,999 - $121,416	5,059	5,059 $121,000

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $249M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Perigon Wealth Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Perigon Wealth Management, LLC with notifications on news.